New lenses show promise for sustained glaucoma treatment

Article

Researchers at University of California, Los Angeles, USA, have developed a new delivery system for treating patients with glaucoma. They have combined nanodiamonds - a by-product of conventional mining and refining processes - with timolol maleate into contact lenses that deliver sustained doses.

Researchers at University of California, Los Angeles, USA, have developed a new delivery system for treating patients with glaucoma. They have combined nanodiamonds - a by-product of conventional mining and refining processes - with timolol maleate into contact lenses that deliver sustained doses.

This new technology has shown great promise for sustained glaucoma treatment. When applied to nanodiamond-embedded lenses, timolol is released when it comes into contact with lysozyme, an enzyme found in tears.

The study was lead by Dr Dean Ho, PhD, MS, professor of oral biology and medicine and co-director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry, and supported by the National Cancer Institute, the National Science Foundation, the Wallace H. Coulter Foundation, The V Foundation for Cancer Research, the Society for Laboratory Automation and Screening, Beckman Coulter Life Sciences, and Singapore's Agency for Science, Technology and Research.

Previously, researchers at UCLA had shown that nanodiamonds could potentially be used to treat other diseases and disorders, including cancer and osteonecrosis of the jaw.

"In addition to nanodiamonds' promise as triggered drug-delivery agents for eye diseases, they can also make the contact lenses more durable during the course of insertion, use and removal, and more comfortable to wear," said Dr Ho, who is also a professor of bioengineering and a member of the Jonsson Comprehensive Cancer Center and the California NanoSystems Institute.

Nanodiamonds - approximately five nanometres in diameter - are small ball-like shapes and can be used to bind a broad spectrum of drug compounds, allowing them to be released over long periods of time.

"Delivering timolol through exposure to tears may prevent premature drug release when the contact lenses are in storage and may serve as a smarter route toward drug delivery from a contact lens," said Kangyi Zhang, co-first author of the study and a graduate student in Dr Ho's lab.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.